Study Finds Texture and Color Enhancement Imaging Improves Colonic Adenoma Detection
Olympus did not initiate, fund, or set or control parameters for the study.
The global burden of colorectal cancer (CRC) is expected to increase by 60%, or more than 2.2 million new cases and 1.1 million deaths, by 2030.1 However, higher detection rates and accurate diagnosis can help reduce the number of deaths from CRC.2
The results from a 2023 multicenter randomized controlled trial published in Gastroenterology reveal Texture and Color Enhancement Imaging (TXI™) technology, available on the Olympus® EVIS X1™ endoscopy system, significantly improves the adenoma detection rate (ADR) and the rate of adenomas per colonoscopy (APC) ≥5mm in size versus white light endoscopy (WLE),3 highlighting its potential in enhancing the quality of colonoscopy screenings.
A Closer Look at TXI Technology
TXI™ technology is an image-processing technology designed to increase the visibility of potentially suspicious lesions and polyps by enhancing image color, texture, and brightness during endoscopic screening without compromising the familiar color spectrum of WLE.4
Study Insights and Data
The multi-centered randomized controlled trial was conducted between March 2021 and April 2023 and included 338 patients. The results found the ADR with TXI technology was significantly higher at 54.60% compared to 40.99% with standard WLE. Notably, TXI technology showed a profound impact in detecting small adenomas (≥5mm in size) and was particularly effective in identifying flat and right-sided polyps, which are challenging to detect. Additionally, TXI technology did not increase needless polypectomies and was associated with a reduction in withdrawal time.3
“This study confirms the efficacy of TXI [technology] for adenoma detection, particularly for flat and right-sided polyps that are more frequently missed at colonoscopy.”
Real-world Benefits
With colorectal cancer being the second leading cause of cancer-related deaths worldwide,5 early detection is crucial. By increasing the ADR and APC, particularly for flat and right-sided polyps, TXI™ technology supports clinicians in identifying potential precancerous lesions.3
Learn More About Advancements
in Colonoscopy Technology
To learn more about TXI™ technology within the EVIS X1™ endoscopy system and how it can help improve detection rates of colorectal cancer, complete the form to connect with an Olympus representative and gain access to a comprehensive summary of the “Texture and Color Enhancement Imaging Improves Colonic Adenoma Detection: A Multicenter Randomized Controlled Trial” study mentioned throughout this article.
TXI™ technology is not intended to replace histopathological sampling as a means of diagnosis.
The EVIS X1™ endoscopy system is not designed for cardiac applications. Other combinations of equipment may cause ventricular fibrillation or seriously affect the cardiac function of the patient. Improper use of endoscopes may result in patient injury, infection, bleeding, and/or perforation. Complete indications, contraindications, warnings, and cautions are available in the Instructions for Use (IFU).
TXI™ technology is a trademark of Olympus Corporation, Olympus America, Inc., and/or their affiliates.
1. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-691.
2. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370(14):1298-1306.
3. Young E, Rajagopalan A, Tee D, et al. Texture and color enhancement imaging improves colonic adenoma detection: A multicenter randomized controlled trial. Gastroenterology. 2024;166(2):338-340.e3.
4. Data on file with Olympus (DC00489968).
5. World Health Organization. Colorectal Cancer. Colorectal cancer (who.int) Published July 11, 2023. Accessed January 30, 2024.
